<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504163</url>
  </required_header>
  <id_info>
    <org_study_id>17-602</org_study_id>
    <nct_id>NCT03504163</nct_id>
  </id_info>
  <brief_title>Pembrolizumab (MK-3475) as First-line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer</brief_title>
  <official_title>Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on&#xD;
      the participant and urothelial cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a phase II trial of Pembrolizumab (MK-3475) as first-line therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who are disease-free</measure>
    <time_frame>6 months</time_frame>
    <description>Response will be assessed utilizing urine cytology, cystoscopy, and TUR biopsies.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab (MK-3475)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Pembrolizumab (MK-3475) administered after TUR as single agent initial therapy. Pembrolizumab (MK-3475) will be administered as a 200 mg IV infusion at 3-week intervals for 9 doses over a 24 week period, unless there is unacceptable toxicity or other reasons to discontinue treatment occur.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab (MK-3475)</intervention_name>
    <description>Pembrolizumab (MK-3475) will be administered as a 200 mg IV infusion at 3-week intervals for 9 doses over a 24 week period.</description>
    <arm_group_label>Pembrolizumab (MK-3475)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          -  Histologically confirmed urothelial cancer by TURBT performed at MSKCC.&#xD;
&#xD;
          -  TURBT within 6 weeks of protocol entry with complete resection of all papillary&#xD;
             lesions.&#xD;
&#xD;
          -  Patients with high risk, BCG-naïve non-muscle-invasive urothelial cancer defined as&#xD;
             having one of the following disease states:&#xD;
&#xD;
               -  T1 on restaging biopsy, plus cis&#xD;
&#xD;
               -  Multiple (≥ 1) T1 recurrences, plus cis&#xD;
&#xD;
               -  Multifocal T1 plus cis&#xD;
&#xD;
               -  T1b, plus cis&#xD;
&#xD;
               -  T1 with lymphovascular invasion plus cis&#xD;
&#xD;
          -  Patient refusal of cystectomy and bilateral pelvic lymphadenectomy&#xD;
&#xD;
          -  No prior intravesical therapy.&#xD;
&#xD;
          -  No prior radiation therapy for bladder cancer. Prior radiation therapy for prostate&#xD;
             cancer is allowed.&#xD;
&#xD;
          -  ECOG performance status 0 or 1.&#xD;
&#xD;
          -  Age ≥ 18 years of age&#xD;
&#xD;
          -  Female subjects of childbearing potential should be willing to use 2 methods of birth&#xD;
             control, be surgically sterile, or abstain from heterosexual activity for the course&#xD;
             of the study through 120 days after the last dose of the study medication (reference&#xD;
             section 9.5.2). Subjects of childbearing potential are those who have not been&#xD;
             surgically sterilized or have not been free from menses for &gt;1 year.&#xD;
&#xD;
          -  Male subjects should agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 120 days after the last dose of study therapy.&#xD;
&#xD;
          -  Patients must not have other invasive malignancies within the past 5 years (with the&#xD;
             exception of non-melanoma skin cancers, localized prostate cancer, and carcinoma in&#xD;
             situ of the cervix).&#xD;
&#xD;
          -  Required Initial Laboratory Values:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 x 10E9/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 10E9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times the upper limit of normal (x ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30 using the CKD-Epi formula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with systemic chemotherapy&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure&#xD;
&#xD;
          -  History of myocardial infarction within 6 months&#xD;
&#xD;
          -  History of stroke within 6 months&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Presence of any systemic metastases (ie, nodal, visceral, or central nervous system)&#xD;
&#xD;
          -  Major surgical procedure (other than TURBT) within 28 days prior to the study&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or lactating&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1 agent, anti-PD-L1 agent, or other inhibitory or&#xD;
             stimulatory agent oriented towards a T-cell receptor&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Known active Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Received live attenuated vaccines within 30 days prior to start of study treatment.&#xD;
             Patients must also agree to avoid live attenuated vaccines during study treatment.&#xD;
&#xD;
          -  Has an active autoimmune disease requiring systemic treatment within the past 3 months&#xD;
             or a documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic or immunosuppressive agents. Subjects with vitiligo, diabetes Type&#xD;
             I, or resolved childhood asthma/atopy would be an exception to this rule. Subjects&#xD;
             that require intermittent use of bronchodilators, inhaled steroids, or local steroid&#xD;
             injections would not be excluded from the study. Subjects with hypothyroidism stable&#xD;
             on hormone replacement or Sjøgren's syndrome will not be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean Bajorin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dean Bajorin, MD</last_name>
    <phone>646-888-4700</phone>
    <email>bajorind@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guido Dalbagni, MD</last_name>
    <phone>646-422-4394</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (All Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Bajorin, MD</last_name>
      <phone>646-888-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (All Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Bajorin, MD</last_name>
      <phone>646-888-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (All protocol activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Bajorin, MD</last_name>
      <phone>646-888-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (All protocol activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Bajorin, MD</last_name>
      <phone>646-888-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering West Harrison (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Bajorin, MD</last_name>
      <phone>646-888-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Bajorin, MD</last_name>
      <phone>646-888-4700</phone>
    </contact>
    <contact_backup>
      <last_name>Guido Dalbagni, MD</last_name>
      <phone>646-422-4394</phone>
    </contact_backup>
    <investigator>
      <last_name>Dean Bajorin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (All Protocol Activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Bajorin, MD</last_name>
      <phone>646-888-4700</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pembrolizumab (MK-3475)</keyword>
  <keyword>17-602</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

